Screener
Iovance Biotherapeutics, Inc. IOVA Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShortTermInvestments.
The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 9:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091716
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Current Assets | ||
| Cash and cash equivalents | $110,768 | $163,078 |
| Trade accounts receivable | 102,119 | 82,448 |
| Short-term investments | 186,906 | 133,902 |
| Inventory | 55,590 | 51,678 |
| Prepaid expenses and other assets | 8,874 | 11,583 |
| Total Current Assets | 464,257 | 442,689 |
| Property and equipment, net | 131,464 | 131,112 |
Item 1.Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Iovance Biotherapeutics, Inc.'s short-term investments?
- Iovance Biotherapeutics, Inc. (IOVA) reported short-term investments of $186.91M in Q2 2026.
- How has Iovance Biotherapeutics, Inc.'s short-term investments changed year-over-year?
- Iovance Biotherapeutics, Inc.'s short-term investments increased by 10.8% year-over-year, from $168.71M to $186.91M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s short-term investments?
- Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s short-term investments has grown at a -24.9% compound annual growth rate (CAGR), from $562.11M to $133.9M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Iovance Biotherapeutics, Inc.'s short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude